27224-09-5

Basic information

• Product Name: 4-BROMO-ISOQUINOLINE-1-CARBONITRILE
• Synonyms: 4-BROMO-ISOQUINOLINE-1-CARBONITRILE
• CAS NO: 27224-09-5
• Molecular Formula: C₁₀H₅BrN₂
• Molecular Weight: 233.06
• Mol File: 27224-09-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 375.328°C at 760 mmHg
• Flash Point: 180.792°C
• Appearance: /
• Density: 1.661g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.703
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-BROMO-ISOQUINOLINE-1-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-ISOQUINOLINE-1-CARBONITRILE(27224-09-5)
• EPA Substance Registry System: 4-BROMO-ISOQUINOLINE-1-CARBONITRILE(27224-09-5)

Safety Data

• Hazardous Substances Data: 27224-09-5(Hazardous Substances Data)

Usage

General Description

4-Bromo-isoquinoline-1-carbonitrile is a chemical compound with the molecular formula C9H5BrN2. It is a brominated derivative of isoquinoline and contains a carbonitrile group. 4-BROMO-ISOQUINOLINE-1-CARBONITRILE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used in the production of other organic compounds and as a building block in chemical reactions. 4-Bromo-isoquinoline-1-carbonitrile is a solid that is light sensitive and should be stored in a cool, dry place away from heat and direct sunlight. It is important to handle this compound with care and use appropriate safety precautions when working with it in a laboratory setting.

InChI:InChI=1/C10H5BrN2/c11-9-6-13-10(5-12)8-4-2-1-3-7(8)9/h1-4,6H

Upstream product

• 3749-21-1 4-bromoisoquinoline N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 
• 1532-97-4 4-bromoisoquinoline 
• 53600-04-7 2-benzoyl-4-bromo-1,2-dihydro-isoquinoline-1-carbonitrile 

Downstream Products

• 573758-64-2 4-(2,4-Dimethoxy-benzylamino)-isoquinoline-1-carbonitrile 
• 573758-69-7 4-Amino-isoquinoline-1-carbonitrile 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.